Clinical trial
A Phase 2, Open-Label, Dose-Escalation Study in Subjects With Pulmonary Arterial Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) Using Inhaled GeNOsyl.
NCT01265888 is registered in ClinicalTrials.gov with Geno LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Dose-Escalation Study in Subjects With Pulmonary Arterial Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) Using Inhaled GeNOsyl.
- Lead sponsor
- Geno LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2011
- Completion date
- September 30, 2016
- Enrollment
- 31 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.